Related coverage linked through entity extraction aliases.
May 07, 2026
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
Jun 16, 2026
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
Jul 24, 2026
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
May 15, 2026
Phase 2 MINDFuL results for XPro1595 in early Alzheimer's disease were published, showing positive trends and no ARIA. FDA aligned on a phase 2b/3 registrational design. Webinar set for Feb 27, 2026.
Apr 27, 2026
A study in Nature Medicine found that a single blood test model using plasma %p-tau217 can estimate when Alzheimer’s symptoms are likely to begin. In 603 patients, the model linked biomarker positivity with symptom onset, with a median error of 3.0 to 3.7 years.
Mar 24, 2026
New research reveals significant advances in blood-based biomarkers for Alzheimer's disease, including a pTau 217 assay showing 93% agreement with amyloid PET imaging and identification of interferon gamma as a diagnostic signal linked to genetic risk. These developments address challenges in early diagnosis and monitoring while requiring substantially less plasma than previous tests.
Mar 17, 2026
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
Mar 14, 2026
New research demonstrates that blood tests measuring p-tau217 protein can identify dementia risk up to 25 years before symptoms and significantly improve diagnostic accuracy in clinical practice.
Mar 13, 2026
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
Feb 20, 2026
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
Feb 16, 2026
Blood-based biomarkers including brain-derived tau and amyloid-beta are enabling earlier Alzheimer's disease diagnosis through non-invasive testing, though confirmatory imaging remains necessary before treatment initiation.
Feb 19, 2026
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
